23 Stock Top Picks and 3 ETF (Jan 25-31)

Since peaking in early 2021, MG has been in a downtrend. Now, it's forming a base. If it breaks $85 and stays there a few weeks, that's good.  But it keeps rubbing against that resistance level and he doesn't see a catalyst to take it higher.

He also owns CP. Some sensitivity to volumes in an economic downturn. Historically, has outperformed the TSX during downturns. Long and strong this name. Wouldn't shy away from adding here, despite economic clouds.

He wouldn't sell a share. Operations and results vs. two years are much much higher. Earnings estimates for 2023 are 30% higher than when the year started. Trades at 6x forward.

They bought a company that screwed up their business, but is now past that and is now fine.

End product is desirable, but supply chains have really hurt it. Reported this morning, and the market is cheering that news. High-risk name. Not for the faint of heart, but perhaps it's turned a corner.

It makes high quality valves for the nuclear industry. It had a take-over offer of $13 a share and he sold at around $12.50. However there were worries that the French Government might block the sale so the stock price dropped. The nuclear valves division is based in France. However he feels that the deal…

Customized, prefabricated environmental office interior solutions. High net cash position. Significant upside because of their flexible business model. Surge in office reconfiguration taking place across North America. Top management. No dividend. (Analysts’ price target is $3.46)

Just bought it. The energy in pullback was overdone. FANG offers secular growth, making good, strategic acquisitions and want to distribute 75% of their cash flow to investors through dividends and buybacks, plus a variable dividend. She bought around $139. China is not yet reflected in energy stocks, and today Russia announced energy output cuts.

(A Top Pick Oct 24/22, Down 14%) Very confident in holding name.Large ownership position.Trading at 39% free cash flow yield.Recent acquisition misunderstood by the market.At least 10 years of high quality inventory.CEO recent bought 900,000 shares.Expecting a ~$14 share price.

(A Top Pick Oct 24/22, Up 39%) Will continue to owns shares.Can't find better names.Singular asset (oil).Excellent balance sheet - almost 0 debt.High oil prices good for business.Trading at ~4x cash flow.35 years of reserves. Expecting ~$45-$50 share price. 

Owns shares (about 5% in portfolio).MEG and Cenovus better options. Good for long term investors (5-10 years).High exposure to oil prices. Expecting 60% upside, or ~$90 share price. 

Just beat earnings and have increased production. Cheap valuation compared to peers. But it's getting more expensive heading into 2021. There's no growth here, but that goes with the entire oil patch. The real issue is will they survive. Their balance sheet is getting better, but still high for a blue-chip name. You'll be saved…

Higher interest rates have been a headwind. Likes the yield on ENB (over 7%) and PPL (6.5%).

Share buybacks total 35-40% in the last 4-5 years. Likes that. 

Hold tight or sell with pending takeover? From today's price, $5.50 is in play. As a shareholder, you have to decide if it's worth holding onto your shares to get your $95 per share. There is a chance that the FTC is successful in challenging the US court order, in which case you'd want to…

MSFT vs. GOOG in terms of AI Though MSFT is up 32% this year vs. GOOG's 49%, he prefers MSFT, because Google fumbled their AI roll-out while MSFT will benefit more from AI, as offered in their suite of services and how it benefits their consumers. Both companies are strong with strong user bases and…

Pandemic challenges continue, especially for labour. Good, long-term business. Costs have increased. Demand is still there. Starting to come back. Debt. Won't see dividend increases soon. If it goes up, take some money off the table. Better places to put your money.

(A Top Pick Dec 15/22, Down 26%) Diversified into a vertically integrated healthcare colossus. Aetna business is weighing them down, but could be temporary. Compelling 8x earnings, very cheap, well capitalized, nice dividend. As long as Americans need healthcare, CVS will be part of that.

(A Top Pick Aug 09/19, Up 10%) A cannabis company in Nevada. Like Indus, they cleaned up their situation and are turning around. They bought a large dispensary in Nevada near Reno. An overhang was owing the vendor a lot of money, but that vendor has become the new CEO has fixed that debt. CXXI…

(A Top Pick May 29/20, Up 55%) Oxygen delivery. Recurring revenue model. Very strong outlook.

Shares have been rocketing, partly because they're using generative AI and their own data more than any insurer to assess risk and therefore making fewer mistakes.

(A Top Pick Jan 12/21, Up 48%) Great-managed REIT. Taken out.

It's real estate in 28 countries. It's something different for Canadians and worth having a look.

(A Top Pick Jan 29/19, Up 1.5%) Global Risk Parity balances the risk of growth and inflation. It balances the risks to keep you level. The peak draw down was 12% -- very manageable in the context of recent volatility.

He's recommended this before and he's negative on this, but he is not leveraged. But he collects a nice coupon in USD each month. The key is to rebalance your portfolio once a year, say December, to buy more or less of this.

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. EPS of -2c slightly missed estimates. Revenue of $75M missed estimates by 10%. EBITDA of $21.3M missed by 8%. Gold sales fell 16% yet all-in costs rose 18%. 2023 forecast is for 120,000 ounces, up from 111,000. Its problems are not unique as costs continue…